20 articles
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
A completed University of Kansas trial investigates whether creatine monohydrate can support brain energy metabolism in Alzheimer's patients.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
12-month trial examined whether oral MK-677 could restore youthful growth hormone levels and improve body composition in healthy seniors.
Large 7-year study tested whether Ginkgo biloba extract could slow progression from memory complaints to dementia in nearly 3,000 adults.
Baylor researchers investigated whether glutathione precursors glycine and NAC could reverse oxidative stress and mitochondrial dysfunction in COVID-19.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
Novel KH-1 supplement containing spermidine and probiotics tested for autophagy stimulation and glucose control in 42 prediabetic participants.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
Small trial explores how popular greens supplement affects microbiome and blood nutrient markers in healthy adults over 7 weeks.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
A Phase 1 trial examines how gadobutrol moves through and exits the bodies of newborns and toddlers undergoing routine contrast MRI.
12-month trial compared anastrozole to testosterone gel in 44 men over 65 with low testosterone levels.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
Phase 3 trial pits next-gen GnRH antagonist degarelix against standard goserelin in prostate cancer hormone suppression.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
Researchers used retinal imaging to detect brain amyloid and tested whether telomerase activation could reduce Alzheimer's markers.
Researchers mapped how anesthetics, nitric oxide, and other drugs alter hemoglobin's grip on oxygen — with real implications for critical care.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
